CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Lumbar Sympathetic Ganglion Blockprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06241820
NCT06241820N/ACompleted

The Success of Lumbar Sympathetic Ganglion Block Using Lower Extremity Perfusion Index: A Prospective Observational Study

Jeongsoo Kim·interventional·Posted Feb 5, 2024·Updated Jul 11, 2024

In Brief

A clinical study evaluating Lumbar Sympathetic Ganglion Block for Chronic Pain and 3 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The patient, who is experiencing chronic pain in the lower extremities persisting for more than three months, is scheduled to undergo lumbar sympathetic ganglion block. To evaluate the technical success of the sympathetic blockade, temperature and perfusion index (PI) will be measured at one-minute intervals over a 20-minute period before and after the procedure on the treated side and the opposite side foot. Additionally, other variables related to the procedure will be assessed before the procedure, after the procedure, before discharge, and during follow-up outpatient visits or phone surveys at 1 week and 1 month after the procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 5, 2024
Enrollment StartFeb 13, 2024
Primary CompletionApr 30, 2024
Study CompletionMay 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.4 years ago

Interventions

Lumbar Sympathetic Ganglion Blockprocedure

A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.